Cancer Research Technology
Log in Register
Menu

Pr8/22 Cell Line

Info

Catalogue Number 153248
Parental Line P388
Host Mouse
Tissue Lymphatic Tissue
Disease Keywords Drug resistant
Model Tumour line
Relevance The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm originating in DBA/2 mouse and converted to ascitic form in the first mouse transfer. Pr8/22 is resistant to daunorubicin and is multi drug resistant (MDR). Cells should be treated with the drug at least once a month and before freezing, however after resuscitating daunorubicin should not be added until the first passage. It is advisable to keep a backup culture which is not drug-challenged.
Production Details The cell line Pr8/22 has been derived from P388, a methylcholanthrene-induced lymphoid neoplasm.
Conditional No
Research Area Cancer, DNA Damage and Repair, Drug Discovery & Development
Growth/Phenotype Keywords Suspension
Recommended Growing Conditions Sub-culture routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage.Culture Medium: RPMI 1640 + 2mM Glutamine + 10% Horse Serum (HS); treat once a month with 0.1µM Daunorubicin.
Cellosaurus ID CVCL_4276

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

McGown et al. 1983. Cancer Chemother Pharmacol. 11(2):113-6. PMID: 6627597.

Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.

Europe PMC ID: 6627597


Add a reference

References: 2 entries

McGown et al. 1983. Cancer Chemother Pharmacol. 11(2):113-6. PMID: 6627597.

Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor